EUCTR2018-004479-11-IT进行中（未招募）1 期
A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent must be obtained prior to participation in the study.
- •2. Age = 18 years at the date of signing the informed consent form (ICF).
- •3. Morphologically confirmed diagnosis of a myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016) by investigator assessment with one of the following Prognostic Risk Categories, based on the International Prognostic Scoring System (IPSS-R):
- •Very high (> 6 points)
- •High (> 4.5-6 points)
- •Intermediate (> 3-4.5 points): a subject determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of = 5% bone marrow blast
- •4. Not eligible at the time of screening, for intensive chemotherapy
- •according to the investigator, based on local standard medical practice
- •and institutional guidelines for treatment decisions.
- •5. Not eligible at the time of screening, for hematopoietic stem-cell
- •transplantation (HSCT) according to the investigator, based on local
- •standard medical practice and institutional guidelines for treatment
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
- •Refer to protocol for complete list of inclusion criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 84
排除标准
- •1. Prior exposure to TIM-3 directed therapy at any time. Prior therapy
- •with immune check point inhibitors (e.g. anti-CTLA4, anti-PD-1, anti-PD
- •or anti-PD-L2), cancer vaccines are allowed except if the drug was
- •administered within 4 months prior to randomization.
- •2. Previous first-line treatment for intermediate, high or very high risk
- •myelodysplastic syndromes (based on IPSS-R) with chemotherapy or
- •any other antineoplastic agents including lenalidomide and
- •hypomethylating agent (HMAs) such as decitabine or azacitidine.
- •3. History of severe hypersensitivity reactions to any ingredient of the
- •study treatment (azacitidine, decitabine or MGB453) or their excipients,
- •or to monoclonal antibodies (mAbs).
- •4. Currently using or used within 14 days prior to randomization of
- •systemic, steroid therapy (> 10 mg/day prednisone or equivalent) or
- •any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic
- •steroids are allowed. Replacement therapy, steroids given in the context
- •of a transfusion are allowed and not considered a form of systemic
- •5. Investigational treatment for MDS received within 4 weeks prior to randomization. In case of a checkpoint inhibitor: 4 months minimum prior to randomization interval is necessary to allow enrollment.
- •6. Active autoimmune disease requiring systemic therapy (e.g. corticosteroids).
- •7. Live vaccine administered within 30 days prior to randomization.
- •Refer to protocol for complete list of exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
A study to test whether pazopanib can prevent or delay kidney tumor coming back after the tumor has been removedRenal Cell CarcinomaEUCTR2010-020965-26-SKovartis Pharma Services AG1,500
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - BAY73-4506 Phase III GIST 3rd/4th lineEUCTR2009-017957-37-FRBayer HealthCare AG170
进行中（未招募）
1 期
16-week efficacy and 3-year safety, tolerability and efficacy of secukinumab in active ankylosing spondylitis patientsEUCTR2013-001090-24-BEovartis Pharma Services AG222
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP). - RAISEEUCTR2006-000470-78-FRGlaxoSmithKline Research and Development Limited
进行中（未招募）
1 期
Study of Reparixin combined with paclitacel compared to paclitaxel alone in patients with metastatic Triple-negative breast cancerEUCTR2014-004796-23-FRDompé Farmaceutici s.p.a.190